Overview
Ruben Mena-Rodriguez practices practicing medicine in Valencia, Spain.
His clinical expertise encompasses Solitary Fibrous Tumor, Hemangioblastoma, and Hydrocephalus.
He is actively involved in clinical research, co-authoring 11 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Ruben Mena-Rodriguez
Is Ruben Mena-Rodriguez a top-rated expert for Solitary Fibrous Tumor?
MediFind is an objective health platform that identifies experts based on real-world data. Ruben Mena-Rodriguez is classified as an Experienced expert for Solitary Fibrous Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Ruben Mena-Rodriguez participate in research or clinical trials?
Yes. Ruben Mena-Rodriguez has published 11 articles and abstracts on conditions like Solitary Fibrous Tumor. You can view a list of Ruben Mena-Rodriguez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- HemangioblastomaMr. Mena-Rodriguez isExperienced. Learn about Hemangioblastoma.
- HydrocephalusMr. Mena-Rodriguez isExperienced. Learn about Hydrocephalus.
- Solitary Fibrous TumorMr. Mena-Rodriguez isExperienced. Learn about Solitary Fibrous Tumor.